A systematic analysis of new commercial investigational new drug applications (IND) submitted to the FDA’s Office of Hematology and Oncology Products …
On June 12, 2025, the Food and Drug Administration approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for adult patients with recurrent low-grade
Meeting information for FDA/The Osteosarcoma Institute (OSI) Workshop
On June 12, 2025, the Food and Drug Administration approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for adult patients with recurrent low-grade
Despite survival gains for many pediatric cancers since the 1970s, cancer remains the leading cause of death by disease for children and adolescents in the…
On June 3, 2025, the Food and Drug Administration (FDA) approved darolutamide.
On June 3, 2025, the Food and Drug Administration (FDA) approved darolutamide.
On June 3, 2025, the Food and Drug Administration (FDA) approved darolutamide.
On June 3, 2025, the Food and Drug Administration (FDA) approved darolutamide.
The integration of artificial intelligence (AI) and machine learning (ML) in oncology clinical trials is rapidly evolving alongside the broader field. For example, AI-driven adaptive…
Jennifer Gao Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD Jennifer Gao, Joyce Cheng, Mallorie Fiero, Shenghui Tang, Suparna Wedam, Melanie…
